1 / 7

WHY INVEST IN YOUNG MEDICAL ONCOLOGISTS?

WHY INVEST IN YOUNG MEDICAL ONCOLOGISTS?. Roberto Labianca Director Department of Oncology and Hematology Ospedali Riuniti Bergamo, Italy. WHO ARE YMO?.

wilma-beard
Download Presentation

WHY INVEST IN YOUNG MEDICAL ONCOLOGISTS?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. WHY INVEST IN YOUNG MEDICAL ONCOLOGISTS? Roberto Labianca Director Department of Oncology and Hematology Ospedali Riuniti Bergamo, Italy

  2. WHO ARE YMO? • YOUNG (besides yourself…): under 21 (as in football: Mario Balotelli)? less than 30 (common sense)? 35 (AIOM)? 40 (ESMO)?...but now all these terms are increasing! • MEDICAL ONCOLOGIST: see the ESMO official definition • In practice: about 70% of doctors working in our Institutions (70-80% women)

  3. WHY? • Because they are “fresh” and creative (you will have a proof very soon!) • Because they still have the dream to win cancer • Because the future of Oncology is in their hands • Because we, as their mentors (or “ differently young people”), have many things to learn from them…and of course many things to teach them • But chiefly because they obtained very important results in this field and have time to obtain other outstanding achievements

  4. WHERE? • In every Oncology Institution (academic or not) • In every day clinical practice • In clinical research • …but chiefly in translational research (they know and understand the molecular pathways better than most of us)… • In Oncology Societies • In Cooperative Groups

  5. HOW? • In National and International Societies (AIOM, ESMO…): promoting specific YMO groups, Masterclasses, dedicated events inside the Congresses… • In Cooperative Groups: stimulating research projects by them • In your Hospitals: accelerating their passage into the “salary” area… • …and creating Units for clinical/translational research with responsability to them • In Pharma world: including them in the advisory boards and in the scientific committees of registrative trials

  6. WHEN ? “Se non ora, quando?” (If not now, when?) Primo Levi Therefore: Just now!!!

  7. BEFORE STARTING… On behalf of the Italian GI oncological community I would thank Florian Lordick for yesterday wishes

More Related